Michael Ray, Vera Bradley, Inc. (VRA)’s insider Sold 33,236 Shares; Last Week PTC Therapeutics, Inc. (PTCT) Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT) Logo

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. PTC Therapeutics had 40 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Wednesday, February 24. On Wednesday, January 20 the stock rating was initiated by Credit Suisse with “Outperform”. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, March 7. The firm earned “Neutral” rating on Tuesday, July 26 by Credit Suisse. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, February 24. The firm has “Buy” rating by Citigroup given on Friday, November 11. The firm has “Buy” rating by Citigroup given on Thursday, February 22. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Underweight” rating given on Wednesday, April 4 by Barclays Capital. Cowen & Co maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, April 18 with “Hold” rating. The rating was maintained by RBC Capital Markets on Wednesday, August 9 with “Hold”. See PTC Therapeutics, Inc. (NASDAQ:PTCT) latest ratings:

18/04/2018 Broker: Cowen & Co Rating: Hold Maintain
04/04/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $24 Downgrade
07/03/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $18 New Target: $24 Maintain
07/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $31.0 Maintain
22/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $35 Maintain
29/01/2018 Broker: RBC Capital Markets Rating: Hold Reinitiate

Company insider, Michael Ray, major shareholder of Vera Bradley Inc sold a total of 33,236 shares of the corporation, based on $14.1 a share. In the last 30 days, he also unloaded 33,236 shares with a total value $379,721 USD. Today, he owns 4.69 million shares or 13.16% of the company’s market capitalization (total value of the shares outstanding).

The stock decreased 0.35% or $0.05 during the last trading session, reaching $14.11. About 336,497 shares traded or 1.32% up from the average. Vera Bradley, Inc. (NASDAQ:VRA) has risen 39.27% since June 13, 2017 and is uptrending. It has outperformed by 26.70% the S&P500. Some Historical VRA News: ; 16/03/2018 – Vera Bradley Closes Above 50-Day Moving Average: Technicals; 14/03/2018 – VERA BRADLEY REPORTS NEW LICENSING PACT FOR SLEEPWEAR/LOUNGEWEA; 14/03/2018 – Vera Bradley Sees 1Q Loss/Shr 8c-Loss 10c; 14/03/2018 – VERA BRADLEY SEES 1Q LOSS/SHR 8.0C TO 10C, EST. LOSS/SHR 11.0C; 14/03/2018 Vera Bradley 4Q EPS 24c; 14/03/2018 – Vera Bradley Announces New Licensing Agreement for Sleepwear/Loungewear; 14/03/2018 – VERA BRADLEY INC VRA.O SEES FY 2019 SHR $0.35 TO $0.45; 14/03/2018 – VERA BRADLEY INC – SEES 2019 NET REVENUES OF $405 TO $425 MLN; 14/03/2018 – Vera Bradley Sees FY Rev $405M-$425M; 14/03/2018 – Vera Bradley Sees 1Q Rev $84M-$89M

Investors sentiment decreased to 1.02 in 2018 Q1. Its down 0.28, from 1.3 in 2017Q4. It fall, as 15 investors sold Vera Bradley, Inc. shares while 34 reduced holdings. 18 funds opened positions while 32 raised stakes. 22.06 million shares or 2.95% more from 21.43 million shares in 2017Q4 were reported. Minnesota-based Us Bank De has invested 0% in Vera Bradley, Inc. (NASDAQ:VRA). Jacobs Levy Equity Mgmt holds 0.01% or 70,314 shares. Tower Rech Cap Ltd Liability (Trc) accumulated 3,568 shares or 0% of the stock. Barrow Hanley Mewhinney And Strauss invested 0.01% of its portfolio in Vera Bradley, Inc. (NASDAQ:VRA). Connor Clark Lunn Invest Mgmt Limited reported 0.01% in Vera Bradley, Inc. (NASDAQ:VRA). Aqr Capital Mngmt Limited Company accumulated 614,944 shares. Bnp Paribas Arbitrage Sa stated it has 6,277 shares or 0% of all its holdings. Pnc Financial Grp Incorporated Inc stated it has 1,174 shares or 0% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% of its portfolio in Vera Bradley, Inc. (NASDAQ:VRA). Trexquant Invest Ltd Partnership, Connecticut-based fund reported 33,409 shares. Mason Street Advsr Limited Liability Corporation holds 0% in Vera Bradley, Inc. (NASDAQ:VRA) or 5,217 shares. Tudor Invest Corporation Et Al holds 0.01% of its portfolio in Vera Bradley, Inc. (NASDAQ:VRA) for 39,234 shares. 30,600 were accumulated by Macquarie Gp Limited. Legal General Gru Public Limited Com, United Kingdom-based fund reported 34,411 shares. Swiss National Bank & Trust invested in 0% or 37,000 shares.

Another recent and important Vera Bradley, Inc. (NASDAQ:VRA) news was published by Nasdaq.com which published an article titled: “Vera Bradley to Present at Robert W. Baird 2018 Global Consumer, Technology & Services Conference in NYC” on May 21, 2018.

Vera Bradley, Inc., together with its subsidiaries, designs, makes, and sells women's handbags, luggage and travel items, fashion and home accessories, and gifts. The company has market cap of $502.81 million. The firm offers totes, crossbodies, satchels, clutches, backpacks, baby, and lunch bags; accessories, inclduing wallets, wristlets, eyeglass cases, jewelry, scarves, and various technology accessories; and travel products, such as rolling luggage, cosmetics, and travel and packing accessories, as well as travel bags comprising duffel and weekend bags. It has a 53.85 P/E ratio. It also provides home products consisting of mugs and tumblers, as well as textiles products, such as throw blankets, beach towels, comforters, and wellness and beauty products; offers apparel/footwear, stationery, merchandising, and gift card products; and licenses its products.

Among 8 analysts covering Vera Bradley (NASDAQ:VRA), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Vera Bradley has $24 highest and $9.0 lowest target. $14.63’s average target is 3.69% above currents $14.11 stock price. Vera Bradley had 29 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, January 15 by Standpoint Research. The stock has “Buy” rating by Wunderlich on Thursday, August 11. The firm earned “Hold” rating on Wednesday, March 14 by Cowen & Co. The stock of Vera Bradley, Inc. (NASDAQ:VRA) earned “Hold” rating by Jefferies on Wednesday, August 30. As per Thursday, September 3, the company rating was maintained by Telsey Advisory Group. The stock of Vera Bradley, Inc. (NASDAQ:VRA) earned “Hold” rating by Robert W. Baird on Wednesday, August 30. Standpoint Research maintained it with “Buy” rating and $18 target in Wednesday, December 9 report. The firm earned “Hold” rating on Monday, September 25 by KeyBanc Capital Markets. The stock of Vera Bradley, Inc. (NASDAQ:VRA) earned “Hold” rating by Robert W. Baird on Thursday, December 21. Telsey Advisory Group maintained Vera Bradley, Inc. (NASDAQ:VRA) on Thursday, December 10 with “Market Perform” rating.

Since March 19, 2018, it had 0 insider buys, and 8 insider sales for $71.39 million activity. Another trade for 33,236 shares valued at $379,721 was made by Ray Michael C. on Wednesday, May 23. Byrne James Bradley also sold $11.99 million worth of Vera Bradley, Inc. (NASDAQ:VRA) on Monday, March 19. Hall Robert J had sold 1.20M shares worth $11.68M. 1.20M shares were sold by Ray Anne Marie, worth $11.68 million on Monday, March 19. Another trade for 1.20 million shares valued at $11.68 million was made by Hall Joan B. on Monday, March 19. Byrne Thomas Farrell II had sold 1.23 million shares worth $11.99 million.

Since January 3, 2018, it had 0 buys, and 5 sales for $240,352 activity. Peltz Stuart Walter sold $40,207 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) on Friday, January 5. Utter Christine Marie sold $7,280 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, January 3. Almstead Neil Gregory sold $1,361 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, January 3. On Friday, June 1 Souza Marcio sold $178,829 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) or 5,161 shares.

Investors sentiment increased to 1.26 in 2018 Q1. Its up 0.28, from 0.98 in 2017Q4. It increased, as 16 investors sold PTC Therapeutics, Inc. shares while 37 reduced holdings. 36 funds opened positions while 31 raised stakes. 38.49 million shares or 8.57% more from 35.45 million shares in 2017Q4 were reported. 244,199 are owned by Barclays Public Lc. Proshare Advsrs Ltd Liability Com holds 24,307 shares or 0% of its portfolio. Peak6 Investments Ltd Partnership invested in 0.01% or 55,443 shares. Sectoral Asset holds 437,934 shares. 73,683 were accumulated by Zuckerman Investment Grp Limited Liability Corporation. Ameriprise holds 0% or 25,412 shares in its portfolio. Guggenheim Capital Limited Liability Com, a Illinois-based fund reported 65,289 shares. Credit Suisse Ag holds 0% or 59,471 shares. Goldman Sachs Group Inc reported 0% stake. State Of Wisconsin Invest Board owns 40,400 shares. Parametric Portfolio Assocs Ltd Liability Corporation reported 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Amer Century Companies accumulated 92,042 shares. The New York-based Jpmorgan Chase & has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Citigroup holds 0.01% or 476,746 shares in its portfolio. Teacher Retirement Of Texas, a Texas-based fund reported 8,723 shares.

The stock decreased 0.45% or $0.17 during the last trading session, reaching $37.79. About 510,899 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 144.83% since June 13, 2017 and is uptrending. It has outperformed by 132.26% the S&P500. Some Historical PTCT News: ; 09/05/2018 – PTC Therapeutics 1Q Rev $56.1M; 24/05/2018 – 2018 Market Spotlight: Duchenne Muscular Dystrophy (DMD) – PTC Therapeutics Leads Industry Sponsors With the Highest Number of Clinical Trials, Followed by GlaxoSmithKline – ResearchAndMarkets.com; 29/05/2018 – D. E. SHAW REPORTS 5.0% PASSIVE STAKE IN PTC THERAPEUTICS; 06/03/2018 – PTC THERAPEUTICS INC SEES FULL YEAR 2018 NET PRODUCT REVENUES TO BE BETWEEN $260 AND $295 MLN; 19/03/2018 – PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4); 06/03/2018 – PTC THERAPEUTICS INC – PTC ANTICIPATES TRANSLARNA NET PRODUCT REVENUE FOR FULL YEAR 2018 TO BE BETWEEN $170 AND $185 MLN; 09/05/2018 – PTC Therapeutics 1Q Loss/Shr 46c; 09/05/2018 – MK&A ACQUIRED BY FORMER PTC THERAPEUTICS PRESIDENT HIRAWAT; 15/05/2018 – J Goldman & Co LP Exits Position in PTC Therapeutics; 06/03/2018 – PTC Therapeutics Sees FY Rev $260M-$295M

More news for PTC Therapeutics, Inc. (NASDAQ:PTCT) were recently published by: Streetinsider.com, which released: “PTC Therapeutics (PTCT) Says CHMP Adopts Positive Opinion for Expansion of Translarna Label” on June 01, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO” and published on June 01, 2018 is yet another important article.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart